Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GIP and Alanine in Type 1 Diabetes
NCT06881472Completed
- Start
- Jan 2025
- Primary completion
- Jan 2026
- Modality
- Recombinant Proteins and Enzymes, Orthosteric Ligands, Peptides
- Countries
- 1
01
Overview
Trial of glucose-dependent insulinotropic polypeptide[1-42] and l-alanine in type 1 diabetes mellitus (T1D) (4 arms). Primary endpoint: Baseline-subtracted Area Under the Curve of Glucagon Concentration at 150 months. Started Jan 2025; status: completed.
02
Drugs
glucose-dependent insulinotropic polypeptide[1-42]l-alanine
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT06881472.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06881472.